Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

BACKGROUND: The efficacy of olanzapine as an antiemetic agent in cancer chemotherapy has been demonstrated. However, few high-quality reports are available on the evaluation of olanzapine’s efficacy and safety at a low dose of 5 mg among patients treated with carboplatin regimens. Therefore, in this...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Yamamoto, Senri, Iihara, Hirotoshi, Uozumi, Ryuji, Kawazoe, Hitoshi, Tanaka, Kazuki, Fujita, Yukiyoshi, Abe, Masakazu, Imai, Hisao, Karayama, Masato, Hayasaki, Yoh, Hirose, Chiemi, Suda, Takafumi, Nakamura, Kazuto, Suzuki, Akio, Ohno, Yasushi, Morishige, Ken-ichirou, Inui, Naoki
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290573/
https://ncbi.nlm.nih.gov/pubmed/34281514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08572-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi